<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prolonged intermittent kidney replacement therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prolonged intermittent kidney replacement therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prolonged intermittent kidney replacement therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan T Kielstein, MD, FASN, FERA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney replacement therapy (KRT) is commonly required in patients with severe acute kidney injury (AKI). Acute KRTs include standard intermittent hemodialysis, peritoneal dialysis, continuous kidney replacement therapies (CKRTs), and hybrid therapies such as prolonged intermittent kidney replacement therapies (PIKRT), still most widely known under the term prolonged intermittent renal replacement therapy (PIRRT).</p><p>This topic reviews PIKRT in AKI. CKRTs are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">"Continuous kidney replacement therapy in acute kidney injury"</a> and  <a class="medical medical_review" href="/z/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1932.html" rel="external">"Drug removal in continuous kidney replacement therapy"</a>.)</p><p>Standard intermittent hemodialysis and peritoneal dialysis for AKI are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a> and  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND INDICATIONS FOR PIKRT</span><span class="headingEndMark"> — </span>PIKRT is a hybrid treatment that provides KRT for an extended period of time (ie, 6 to 18 hours) but is intermittent (at least three times per week) [<a href="#rid1">1</a>]. PIKRT includes both convective (ie, hemofiltration) and diffusive (ie, hemodialysis) therapies, depending on the method of solute removal [<a href="#rid1">1</a>].</p><p>Other terms used to describe PIKRT include sustained low-efficiency (daily) dialysis (SLED or SLEDD), sustained low-efficiency (daily) diafiltration (SLEDD-f), extended daily dialysis (EDD), slow continuous dialysis (SCD), go slow dialysis, and accelerated venovenous hemofiltration (AVVH) or hemodiafiltration (AVVHDF) [<a href="#rid2">2-5</a>].</p><p>The indication for PIKRT is dialysis-requiring acute kidney injury (AKI) in a patient who is too hemodynamically unstable to tolerate standard intermittent hemodialysis. In most institutions, standard intermittent hemodialysis (eg, four hours of hemodialysis, three times weekly) is the preferred modality for hemodynamically stable patients with severe AKI. Continuous KRT (CKRT) is preferred to standard intermittent hemodialysis for hemodynamically unstable patients, particularly in the setting of large, ongoing fluid administration.</p><p>PIKRT is an alternative to CKRT for hemodynamically unstable patients, although the evidence is weak [<a href="#rid2">2,6-12</a>]. Similar to CKRT, blood pressures are more stable on PIKRT compared with standard intermittent KRT because the rate of solute and fluid removal is slower [<a href="#rid4">4</a>]. One specific system, the GENIUS batch dialysis machine, also contributes to hemodynamic stability by a spontaneous cooling of the dialysate, which mildly decreases body core temperature [<a href="#rid13">13</a>]. Should one choose to utilize cool dialysate for blood pressure support, it can be accommodated by most standard hemodialysis machines used in PIKRT. </p><p>Metabolic control is comparable with CKRT [<a href="#rid14">14-16</a>], and mortality with PIKRT appears to be comparable with other forms of KRT, including CKRT in critically ill patients with AKI [<a href="#rid17">17-20</a>]. Moreover, a time-series analysis of three intensive care units (ICUs) from three different countries showed that a change from CKRT to PIKRT was not associated with a change in mortality risk [<a href="#rid21">21</a>], even when accounting for patient illness severity and underlying trends for improvement in mortality rates of AKI patients over time [<a href="#rid22">22-24</a>].</p><p>PIKRT is useful if the patient requires multiple procedures that would interrupt CKRT [<a href="#rid2">2-5,25-29</a>]. In order to deliver an adequate dialysis dose, CKRT needs to be operating with as few interruptions as possible over 24 hours. Because PIKRT incorporates scheduled time off dialysis (and off anticoagulation, which is often required for both CKRT and PIKRT) procedures may be performed without compromising the dialysis dose.</p><p>In some institutions, PIKRT is used to transition patients from CKRT to standard intermittent hemodialysis as hemodynamic stability improves. PIKRT allows for greater mobilization and rehabilitation of patients because of scheduled time off dialysis [<a href="#rid30">30</a>].</p><p>We use CKRT rather than intermittent hemodialysis, including PIKRT, for patients with acute brain injury or other causes of increased intracranial pressure who have AKI [<a href="#rid31">31</a>]. This is because intermittent hemodialysis is more likely to worsen cerebral edema via a decrease in mean arterial pressure (which causes compensatory cerebral vasodilation) and via a rapid removal of urea resulting in a shift of water to the intracellular space. Limited data, however, suggest that PIKRT is safe for such patients [<a href="#rid32">32-36</a>].</p><p>One meta-analysis found no statistically significant difference between PIKRT and CKRT with regard to patient-centered outcomes such as mortality, kidney function recovery, dialysis dependence, length of intensive care unit stay, and fluid removal rate [<a href="#rid37">37</a>]. Phosphate removal was, however, higher in PIKRT as compared with CKRT.</p><p class="headingAnchor" id="H2665349935"><span class="h1">DIALYSIS MACHINES AND HEMODIALYZERS</span><span class="headingEndMark"> — </span>PIKRT can be performed on most machines that are used for standard intermittent hemodialysis. Machines used for PIKRT should have the capability to run at low blood and dialysate flow rates. Some machines are designed specifically for PIKRT and have specific capabilities for solute removal by convection, diffusion, or both [<a href="#rid1">1</a>]. Modern hemodialysis machines used for PIKRT are one-half to one-third the price of machines specifically designed for continuous KRT (CKRT).</p><p>Standard extracorporeal circuit tubing and hemodialyzers are used for PIKRT. We generally use high-flux dialyzers. Other membranes may result in lower clearance [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/1868.html" rel="external">"Biochemical mechanisms involved in blood-hemodialysis membrane interactions", section on 'Composition of dialysis membranes'</a>.)</p><p>High-cutoff dialyzers have been studied in PIKRT. High-cutoff dialyzers use a membrane that allows clearance of larger solutes compared with high-flux membranes. PIKRT with high-cutoff membranes may provide better clearance of middle molecules, but the clinical significance of this is not known [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H2151393308"><span class="h1">AVAILABILITY</span><span class="headingEndMark"> — </span>Prior to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a survey of dialysis directors of all Veterans Affairs facilities providing inpatient hemodialysis found that over half of the respondents had the capabilities at their facilities to perform PIKRT [<a href="#rid40">40</a>]. During the pandemic, "walkaway" PIKRT, a joint discipline between the intensive care unit (ICU) and nephrology department, experienced even more widespread use [<a href="#rid41">41</a>]. After determination of the treatment goals, the dialysis staff start the treatment and subsequently hand over treatment to the ICU nurse  (<a class="graphic graphic_figure graphicRef138779" href="/z/d/graphic/138779.html" rel="external">figure 1</a>). During hand over, the ICU nurse is instructed on how to adjust the ultrafiltration rate. The dialysis nurse then "walks away" but returns periodically to check on the treatment coordinates. Throughout the treatment, the dialysis staff is reachable and can address problems within a short period of time.</p><p>In Europe, popularity of PIKRT increased from the mid-1990s but was curbed by regulatory actions involving the use of citrate anticoagulation with the GENIUS dialysis system [<a href="#rid42">42</a>]. Presently, 36 percent of all the ICUs in Germany perform PIKRT [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H421227972"><span class="h1">VASCULAR ACCESS</span><span class="headingEndMark"> — </span>A nontunneled or tunneled dialysis catheter in a central vein is the preferred access for PIKRT, even among end-stage kidney disease (ESKD) patients who have an arteriovenous fistula (AVF) or graft (AVG). (See  <a class="medical medical_review" href="/z/d/html/1843.html" rel="external">"Central venous catheters for acute and chronic hemodialysis access and their management"</a>.)</p><p>We do not routinely use the AVG/AVF for PIKRT, because the prolonged placement of needles during PIKRT increases the risk of bleeding or injury to the AVG/AVF. However, if there is specific training and careful oversight, AVFs and AVGs may be used if central access cannot be obtained or is not feasible (as for a patient who is anticipated to have only a short stay in the intensive care unit [ICU]) [<a href="#rid44">44</a>]. Among such patients, the AVF/AVG should be closely monitored to make sure the needles are not dislodged during the prolonged treatment [<a href="#rid1">1</a>]. The use of cutaneous or surface blood detectors over the needles is common when AVFs or AVGs are used in this setting.</p><p class="headingAnchor" id="H4230859441"><span class="h1">PRESCRIPTION</span><span class="headingEndMark"> — </span>For each session, the prescription should specify the time on dialysis, the dialysate composition and flow rate, the ultrafiltration goal and rate, the blood flow rate, and the method of anticoagulation, if any.</p><p class="headingAnchor" id="H3718530539"><span class="h2">Session length</span><span class="headingEndMark"> — </span>PIKRT should be performed at least three times per week to provide an adequate dialysis dose. The time per session ranges from 6 to 18 hours but is typically approximately eight hours. The length of the dialysis session depends on the needs of the patient (usually the volume that needs to be removed) and hemodynamic stability.</p><p>The time per individual session is often determined after assessing the patient response to the initial ultrafiltration rate (fluid removal per hour). As an example, for a severely volume-overloaded patient who requires the removal of large amount of fluid but is hemodynamically unstable, the ultrafiltration rate should be set as low as possible initially and gradually increased until the maximum tolerable ultrafiltration rate is determined by trial and error. The ultrafiltration goal (ie, desired amount of fluid to be removed in the session) is divided by the maximum tolerable ultrafiltration rate to determine the session length. </p><p>The dialysis time may also be determined by other nondialysis-related factors such as scheduling of procedures.</p><p class="headingAnchor" id="H3072906367"><span class="h2">Dialysate composition</span><span class="headingEndMark"> — </span>Dialysate for PIKRT is either generated on-line, mixed from prepackaged salts prior to the treatment, or provided by the dialysis company as prepackaged fluid [<a href="#rid45">45-49</a>].</p><p>The optimal dialysate composition varies based on the anticipated duration of treatment. In general, when the duration of PIKRT is eight hours or more, the dialysate solution generally contains the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium of 4 mEq/L</p><p class="bulletIndent1"><span class="glyph">●</span>Bicarbonate of 24 to 28 mEq/L</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium of 2.5 to 3.0 mEq/L</p><p></p><p>When the duration of PIKRT is less than eight hours, the dialysate solution generally contains the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium of 3 mEq/L</p><p class="bulletIndent1"><span class="glyph">●</span>Bicarbonate of 28 to 32 mEq/L</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium of 2 to 3.5 mEq/L</p><p></p><p>Other constituents (such as sodium and glucose) do not change with duration of treatment.</p><p>Several vendors produce a commercially available dialysate that uses citrate instead of acetic acid in the acid concentrate, although it is used infrequently. Citrate use has been reported to decrease extracorporeal circuit clotting during intermittent hemodialysis [<a href="#rid50">50,51</a>]. However, there are insufficient published data to recommend the use of citrate dialysate for this purpose.</p><p class="headingAnchor" id="H2229804711"><span class="h2">Dialysate flow rate</span><span class="headingEndMark"> — </span>The dialysate flow rate ranges from 100 to 300 mL/min. We use a higher flow rate, at least initially, for patients with severe acidosis or electrolyte abnormalities since a higher dialysis flow rate allows better solute clearance. However, the dialysate flow rate is also adjusted for the anticipated duration of the session since there is a finite amount of dialysate volume available per session (which is preset by the dialysis machine or by the packaging of dialysate fluid).</p><p>As an example, we initially use a dialysate flow rate of 300 mL/min for individuals with severe acidosis or hyperkalemia. We decrease the dialysate flow rate to 100 or 200 mL/min if the anticipated session length is increased to ≥8 hours, whereas we continue to use a dialysate flow rate of 300 mL/min if the session is expected to be &lt;8 hours.</p><p>As noted, the session time is influenced by tolerance to ultrafiltration, and unstable patients who do not tolerate the initially set ultrafiltration rate often have the session time lengthened after starting PIKRT (see <a class="local">'Session length'</a> above). In such patients, the dialysate flow rate must be decreased so that there is a sufficient supply of dialysate to last the entire session since some machines allow only 90 liters of dialysate per session (90 L/10 hours = QD 150 mL/min). Similarly, a jug of dialysate concentrate will last approximately six hours at a QD of 300 mL/min but 18 hours at a QD of 100 mL/min.</p><p>The dialysate flow rates used with PIKRT are lower than those used with standard intermittent hemodialysis (usually approximately 500 mL/min). The rate of solute removal achieved with low dialysate flow rates has been studied in the setting of continuous arteriovenous hemodialysis and to some extent in slow daily hemodialysis [<a href="#rid52">52</a>]. The ratio of dialysate flow rate to blood flow rate is a major determinant of dialysate saturation, such that the lower the ratio, the greater the saturation. This is relevant when dialysate is the scarce commodity. The degree to which dialysate is saturated with urea (expressed as the percentage ratio of dialysate urea nitrogen to blood urea nitrogen [DUN/BUN]) determines the efficacy of the treatment. Up to a QD of 30 to 50 mL/min, the DUN/BUN approaches 100 percent, implying complete saturation of dialysate with urea [<a href="#rid53">53</a>].</p><p>At these low flow rates, diffusive urea clearance is numerically equal to, and therefore limited by, dialysate flow. However, increasing QD above these rates leads to proportionally decreasing gains in urea clearance as the DUN/BUN progressively falls, although this is also dependent upon blood flow [<a href="#rid53">53</a>].</p><p>This phenomenon is illustrated in the figure  (<a class="graphic graphic_figure graphicRef60742" href="/z/d/graphic/60742.html" rel="external">figure 2</a>), where urea clearances were studied in an in vitro system of continuous venovenous hemodialysis (CVVHD) under conditions of different blood and dialysate flows. The flattening of the curves describes the conditions where increases in blood flow rate do not enhance clearance. The greater the dialysate flow rate, the less likely the plateau will occur [<a href="#rid54">54,55</a>].</p><p>Large differences in the technical success or patient outcomes of different dialysate flow rates in PIKRT have not been shown. These prescription variables all interrelate.</p><p class="headingAnchor" id="H1221712831"><span class="h2">Ultrafiltration goal</span><span class="headingEndMark"> — </span>The ultrafiltration goal is the amount of fluid that the clinician wishes to remove during the treatment session. The ultrafiltration goal generally varies between 0 and 6 L per treatment, with an average of approximately 3 L. The goal is determined by the volume status, the patient's ongoing fluid requirement (eg, enteral or total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> and intravenous antibiotics) and the cumulative fluid accumulation since the intensive care unit (ICU) admission [<a href="#rid56">56</a>].</p><p>Volume overload should be expressed in relative terms (eg, 5 or 10 percent over the body weight on admission) and in absolute terms (eg, +3.7 L). Using absolute terms alone may be misleading since the clinical impact of an absolute volume excess of 3.7 liters would be different in a 120 kg or 42 kg patient.</p><p>Volume status is determined in part by physical examination, hemodynamic indices, and with the use of other invasive and noninvasive techniques. (See  <a class="medical medical_review" href="/z/d/html/1854.html" rel="external">"Acute hemodialysis prescription", section on 'Ultrafiltration'</a>.)</p><p class="headingAnchor" id="H2370870785"><span class="h2">Ultrafiltration rate</span><span class="headingEndMark"> — </span>The rate is the amount of fluid removed per hour. Ideally, ultrafiltration rate is normalized to weight, such mL/kg/hour.</p><p>The rate is determined by hemodynamic stability and the urgency to remove excess fluid. Setting the initial ultrafiltration rate requires clinical judgment. Among hemodynamic unstable patients, we start with a little as 50 mL/hour and increase over time. Among patients who are severely volume overloaded but have a stable blood pressure, we will start with a much higher ultrafiltration rate in order to prevent intubation.</p><p>Among volume-overloaded patients, we continue the maximum ultrafiltration rate that is tolerated by the patient and set the treatment time accordingly. (See <a class="local">'Session length'</a> above.)</p><p class="headingAnchor" id="H201756532"><span class="h2">Blood flow</span><span class="headingEndMark"> — </span>We use the highest blood flow (QB) that the catheter will allow (generally 300 to 400 mL/min). Higher blood flows may prevent clotting of the extracorporeal circuit tubings and hemodialyzers. High blood flows do not worsen hemodynamic instability.</p><p>We do not increase the blood flow to increase clearance, particularly if the dialysate flow rate is low. With low dialysate flow rates, increasing the blood flow does not have a large effect on solute clearance, since dialysate is saturated  (<a class="graphic graphic_figure graphicRef60742" href="/z/d/graphic/60742.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H2918126131"><span class="h2">Anticoagulation</span><span class="headingEndMark"> — </span>We generally use anticoagulation to prevent clotting of the extracorporeal system [<a href="#rid8">8</a>]. However some clinicians choose to not use anticoagulation in all patients, at least initially. Better clinical outcomes have not been shown with anticoagulation versus no anticoagulation in PIKRT.</p><p>Methods of anticoagulation include systemic <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> (RCA). The approach varies among institutions and between the authors of this topic. Both approaches are described:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin </strong>– One approach is to use heparin in all patients unless there is a contraindication (generally bleeding). We give heparin 1000 to 2000 unit bolus (15 to 20 units/kg), followed by an infusion of 500 to 1000 units/hour to keep the activated partial thromboplastin time (aPTT) 10 to 20 seconds above or 1.5 times the upper limit of the normal range [<a href="#rid2">2,8,57-60</a>].</p><p></p><p class="bulletIndent1">An alternate approach is to administer an initial bolus of 1000 to 2000 units (15 to 20 units/kg) followed by a continuous infusion of 2 to 5 units/mL of heparin in 0.9 percent <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solution administered at 7.5 units/kg/hour. The excess fluid administered with this method is accounted for in the total ultrafiltration goal for the dialysis session. With this regimen, we aim for aPTT of 35 to 50 seconds, unless the patient has recurrent clotting. If a patient develops recurrent clotting, then the aPTT goal is gradually increased, to balance the risk of recurrent clotting and bleeding. </p><p></p><p class="bulletIndent1">If there is a contraindication to heparin, we attempt PIKRT without anticoagulation. If treatments are repeatedly interrupted because of clotting of the extracorporeal system, we use <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> [<a href="#rid14">14,61,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a> and  <a class="medical medical_review" href="/z/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">Regional citrate anticoagulation</a><strong> (RCA) –</strong> An alternative approach is to use RCA in all patients. RCA is a safe method of anticoagulation in almost all ICU patients [<a href="#rid63">63</a>]. In a study including 282 patients on PIKRT, citrate anticoagulation using a 30 percent citrate solution was superior to heparin in preventing severe bleeding and circuit clotting [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">We use low-calcium dialysate (0 to 1 mmol/L [<a href="#rid62">62</a>]) and infuse a 3 or 4 percent sodium citrate solution into the arterial line of the extracorporeal circuit. The citrate infusion is adjusted to target postfilter ionized calcium concentration of 0.5 to 0.7 mmol/L [<a href="#rid65">65-67</a>].</p><p></p><p class="bulletIndent1">There should be routine surveillance of the citrate infusions and routine laboratory monitoring during PIKRT. We check the blood calcium after 30 and 120 minutes and then at hours 4, 8, and 12 during treatment. We give intravenous calcium if the ionized calcium is &lt;0.9 mmol/L. (See  <a class="medical medical_review" href="/z/d/html/826.html" rel="external">"Treatment of hypocalcemia", section on 'Intravenous calcium dosing'</a>.)</p><p></p><p class="bulletIndent1">PIKRT with citrate anticoagulation may cause hypernatremia and metabolic alkalosis. Hypernatremia and metabolic alkalosis can be corrected by lowering the dialysate sodium and bicarbonate concentrations, respectively, by increasing the dialysate flow rate, or adding an infusion of 0.45 percent <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>.</p><p></p><p class="headingAnchor" id="H3082705829"><span class="h1">DRUG DOSING</span><span class="headingEndMark"> — </span>Drug clearance can be considerable with PIKRT [<a href="#rid68">68-71</a>]. Dosing decisions need to be made on an individual basis depending on drug characteristics [<a href="#rid72">72</a>]. Only anti-infective drugs have been specifically studied [<a href="#rid73">73-94</a>]. As for other forms of KRT, anticancer drugs have only been anecdotally studied [<a href="#rid95">95,96</a>]. </p><p class="headingAnchor" id="H2877108636"><span class="h1">MONITORING FOR ADEQUACY OF TREATMENT</span><span class="headingEndMark"> — </span>We check daily labs including blood urea nitrogen (BUN), creatinine, electrolytes, ionized calcium, and phosphate in order to determine whether an adequate amount dialysis is being delivered.</p><p>We generally do not perform urea clearance tests (ie, urea reduction ratio or Kt/V) unless daily labs suggest inadequate dialysis (such as persistently elevated BUN or creatinine despite treatment). The Kt/V may not provide an accurate measure of dialysis adequacy in PIKRT [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>Monitoring and adjustment of the dialysis prescription is usually done in collaboration between the nephrologist and intensive care unit (ICU) staff [<a href="#rid13">13</a>]. In one model, PIKRT is prescribed by a nephrologist after discussion of the treatment goals for the day with the intensivist. The treatment is initiated and ended by the dialysis nurse but supervised by both dialysis and intensive care nurses, who also adjust treatment settings such as ultrafiltration rate to the (changing) clinical condition [<a href="#rid13">13</a>]. There are many possible practice models in different institutions, however. Remote monitoring of the machines for PIKRT might provide a new option to facilitate treatment surveillance in the setting of staff shortage [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H13"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The major complications of PIKRT are hypotension and abnormalities in serum electrolytes, albumin, calcium, and phosphate.</p><p class="headingAnchor" id="H1345048049"><span class="h2">Hypotension</span><span class="headingEndMark"> — </span>PIKRT is generally well tolerated [<a href="#rid99">99,100</a>]. In some series, a minor, temporary increase in inotrope dose may occur, particularly in the sickest patients who have been hemodynamically unstable prior to starting dialysis [<a href="#rid8">8,57</a>]. In the literature as a whole, between 0 and 7 percent of patients were reported to have discontinued hybrid treatment because of intractable hypotension. However, most of these patients were also subsequently unsupportable on continuous kidney replacement therapy (CKRT) [<a href="#rid14">14,57</a>].</p><p>The most rigorous assessment of hemodynamic stability during hybrid treatments is from a randomized, controlled trial that compared CKRT with PIKRT among 39 critically ill patients [<a href="#rid60">60</a>]. There was no significant difference between treatments in inotrope dose or number.</p><p class="headingAnchor" id="H3302567794"><span class="h2">Abnormalities of electrolytes, calcium, and phosphate</span><span class="headingEndMark"> — </span>Electrolyte concentrations are usually maintained within normal limits.</p><p>Hypophosphatemia commonly occurs with prolonged or frequent PIKRT and requires phosphate supplementation [<a href="#rid14">14,57</a>]. One study found that the frequency of hypophosphatemia increased after the first through the third PIKRT session [<a href="#rid101">101</a>]. We treat hypophosphatemia with intravenous phosphate. This approach is associated with a decrease of ICU mortality as compared with not substituting phosphate [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment", section on 'Intravenous dosing'</a>.)</p><p>PIKRT with <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> (RCA) may cause metabolic alkalosis [<a href="#rid65">65</a>] and hypernatremia.</p><p class="headingAnchor" id="H2047397886"><span class="h2">Albumin and amino acid losses</span><span class="headingEndMark"> — </span>Albumin removal is negligible during PIKRT. However, amino acid removal, particularly glutamine, may be significant, depending upon the PIKRT regimen [<a href="#rid102">102,103</a>] and the dialyzer used for PIKRT [<a href="#rid104">104</a>]. Protein intake may need to be increased during PIKRT. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="headingAnchor" id="H1945729670"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and indications </strong>– Prolonged intermittent kidney replacement therapy (PIKRT) provides intermittent dialysis with long session durations. Solute and fluid removal are slower than with standard intermittent hemodialysis but faster than with continuous kidney replacement therapy (CKRT). PIKRT allows for time for procedures without compromising the dialysis dose. PIKRT also allows greater mobilization and rehabilitation of patients. (See <a class="local">'Definition and indications for PIKRT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis machines </strong>– PIKRT can be performed on most machines that are used for intermittent hemodialysis. Machines used for PIKRT should have the capability to run at low blood and dialysate flow rates. (See <a class="local">'Dialysis machines and hemodialyzers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular access </strong>– The preferred access for PIKRT is a dialysis catheter in a central vein. Among patients with end-stage kidney disease, we generally do not use the arteriovenous fistula (AVF) or graft (AVG), even if available, because of the risk of bleeding or injury. However, if there is specific training and careful oversight, AVFs and AVGs may be used, particularly if central access cannot be obtained or is not feasible (as for a patient who is expected to have only a short stay in the intensive care unit [ICU]). Cutaneous blood leak monitors over needle placement sites are commonly used to improve safety. (See <a class="local">'Vascular access'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prescription</strong> – PIKRT is performed at least three times per week. The time per session is typically approximately eight hours and ranges from 6 to 18 hours depending on the needs of the patient and tolerance to ultrafiltration. The dialysis time may also be determined by other nondialysis-related factors such as scheduling of procedures. Our prescription is defined above. (See <a class="local">'Prescription'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– To assess that adequate dialysis is being delivered, we check daily labs including blood urea nitrogen (BUN), creatinine, electrolytes, ionized calcium, and phosphate. We do not perform urea clearance tests (ie, urea reduction ratio or Kt/V) unless daily labs suggest inadequate dialysis (such as persistently elevated BUN or creatinine). (See <a class="local">'Monitoring for adequacy of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– The major complications of PIKRT are hypotension and hypophosphatemia. There may be loss of albumin and amino acids, requiring adjustment of protein intake. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="headingAnchor" id="H1729956"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mark R Marshall, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Edrees F, Li T, Vijayan A. Prolonged Intermittent Renal Replacement Therapy. Adv Chronic Kidney Dis 2016; 23:195.</a></li><li><a class="nounderline abstract_t">Naka T, Baldwin I, Bellomo R, et al. Prolonged daily intermittent renal replacement therapy in ICU patients by ICU nurses and ICU physicians. Int J Artif Organs 2004; 27:380.</a></li><li><a class="nounderline abstract_t">Bellomo R, Baldwin I, Fealy N. Prolonged intermittent renal replacement therapy in the intensive care unit. Crit Care Resusc 2002; 4:281.</a></li><li><a class="nounderline abstract_t">Marshall MR, Golper TA, Shaver MJ, Chatoth DK. Hybrid renal replacement modalities for the critically ill. Contrib Nephrol 2001; :252.</a></li><li><a class="nounderline abstract_t">Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial 2011; 24:142.</a></li><li><a class="nounderline abstract_t">Holt BG, White JJ, Kuthiala A, et al. Sustained low-efficiency daily dialysis with hemofiltration for acute kidney injury in the presence of sepsis. Clin Nephrol 2008; 69:40.</a></li><li><a class="nounderline abstract_t">Berbece AN, Richardson RM. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int 2006; 70:963.</a></li><li><a class="nounderline abstract_t">Marshall MR, Ma T, Galler D, et al. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dial Transplant 2004; 19:877.</a></li><li><a class="nounderline abstract_t">Fiaccadori E, Maggiore U, Parenti E, et al. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant 2007; 22:529.</a></li><li><a class="nounderline abstract_t">Gashti CN, Salcedo S, Robinson V, Rodby RA. Accelerated venovenous hemofiltration: early technical and clinical experience. Am J Kidney Dis 2008; 51:804.</a></li><li><a class="nounderline abstract_t">Faulhaber-Walter R, Hafer C, Jahr N, et al. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant 2009; 24:2179.</a></li><li><a class="nounderline abstract_t">Marcelino P, Marum S, Fernandes AP, Ribeiro JP. [Hybrid or continuous renal replacement techniques for unstable haemodynamic patients in the intensive care unit]. Acta Med Port 2006; 19:275.</a></li><li><a class="nounderline abstract_t">Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2:32.</a></li><li><a class="nounderline abstract_t">Kumar VA, Yeun JY, Depner TA, Don BR. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report. Int J Artif Organs 2004; 27:371.</a></li><li><a class="nounderline abstract_t">Marshall MR, Golper TA, Shaver MJ, et al. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis 2002; 39:556.</a></li><li><a class="nounderline abstract_t">Depner T, Craig M, Hu K, et al. Solute kinetics during extended daily hemodialysis in the intensive care unit (ICU). ASAIO J 1999; 45:185A.</a></li><li><a class="nounderline abstract_t">Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40:875.</a></li><li><a class="nounderline abstract_t">Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28:29.</a></li><li><a class="nounderline abstract_t">Pannu N, Klarenbach S, Wiebe N, et al. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008; 299:793.</a></li><li><a class="nounderline abstract_t">Zhao Y, Chen Y. Effect of renal replacement therapy modalities on renal recovery and mortality for acute kidney injury: A PRISMA-compliant systematic review and meta-analysis. Semin Dial 2020; 33:127.</a></li><li><a class="nounderline abstract_t">Marshall MR, Creamer JM, Foster M, et al. Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011; 26:2169.</a></li><li><a class="nounderline abstract_t">Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.</a></li><li><a class="nounderline abstract_t">Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 2005; 118:827.</a></li><li><a class="nounderline abstract_t">Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9:R700.</a></li><li><a class="nounderline abstract_t">Ponce D, Abrão JM, Albino BB, Balbi AL. Extended daily dialysis in acute kidney injury patients: metabolic and fluid control and risk factors for death. PLoS One 2013; 8:e81697.</a></li><li><a class="nounderline abstract_t">Annigeri RA, Nandeesh V, Karuniya R, et al. Impact of dialysis practice patterns on outcomes in acute kidney injury in Intensive Care Unit. Indian J Crit Care Med 2016; 20:14.</a></li><li><a class="nounderline abstract_t">Overberger P, Pesacreta M, Palevsky PM, VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2007; 2:623.</a></li><li><a class="nounderline abstract_t">Ricci Z, Ronco C, D'Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006; 21:690.</a></li><li><a class="nounderline abstract_t">Basso F, Ricci Z, Cruz D, Ronco C. International survey on the management of acute kidney injury in critically ill patients: year 2007. Blood Purif 2010; 30:214.</a></li><li><a class="nounderline abstract_t">Bagshaw SM, Darmon M, Ostermann M, et al. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury. Intensive Care Med 2017; 43:841.</a></li><li><a class="nounderline abstract_t">Macedo E, Mehta RL. Continuous Dialysis Therapies: Core Curriculum 2016. Am J Kidney Dis 2016; 68:645.</a></li><li><a class="nounderline abstract_t">Szamosfalvi B, Frinak S, Yee J. Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010; 29:204.</a></li><li><a class="nounderline abstract_t">Bandyopadhyay S, Jakobson D, Chhabra KD, Baker A. Improvement of cerebral blood flow patterns in hepatorenal syndrome using sustained low-efficiency dialysis. Br J Anaesth 2010; 105:547.</a></li><li><a class="nounderline abstract_t">Iarustovskiĭ MB, Nazarova EI. [Hybrid technologies of renal replacement therapy in the treatment of multiple organ failure in cardiosurgical patients]. Anesteziol Reanimatol 2006; :67.</a></li><li><a class="nounderline abstract_t">Iorio L, Violi F, Simonelli R, et al. [Sustained low-efficiency dialysis (SLED) in patients with prevalent systolic heart failure refractory to medical treatment and with chronic renal failure]. G Ital Nefrol 2006; 23 Suppl 34:S71.</a></li><li><a class="nounderline abstract_t">Violi F, Nacca RG, Iengo G, Iorio L. [Long-term sustained low efficiency dialysis in eight patients with class IV NYHA heart failure resistant to high-dose diuretic treatment]. G Ital Nefrol 2009; 26 Suppl 46:50.</a></li><li><a class="nounderline abstract_t">Dalbhi SA, Alorf R, Alotaibi M, et al. Sustained low efficiency dialysis is non-inferior to continuous renal replacement therapy in critically ill patients with acute kidney injury: A comparative meta-analysis. Medicine (Baltimore) 2021; 100:e28118.</a></li><li><a class="nounderline abstract_t">Relton S, Greenberg A, Palevsky PM. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992; 38:M691.</a></li><li><a class="nounderline abstract_t">Schmidt JJ, Hafer C, Clajus C, et al. New high-cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: a clinical crossover comparison in extended dialysis. Blood Purif 2012; 34:246.</a></li><li><a class="nounderline abstract_t">Vangala C, Shah M, Dave NN, et al. The landscape of renal replacement therapy in Veterans Affairs Medical Center intensive care units. Ren Fail 2021; 43:1146.</a></li><li><a class="nounderline abstract_t">Burgner A, Golper T. Walkaway PIRRT (as SLED) for Acute Kidney Injury. Clin J Am Soc Nephrol 2020; 16:138.</a></li><li><a class="nounderline abstract_t">Beige J. Patient safety in hemodialysis from the point of view of the DGfN equipment commission. The Nephrologist 2021; 5.</a></li><li><a class="nounderline abstract_t">Willam C, Meersch M, Herbst L, et al. [Present practise patterns of renal replacement therapy in German intensive care medicine]. Med Klin Intensivmed Notfmed 2022; 117:367.</a></li><li><a class="nounderline abstract_t">Al Rifai A, Sukul N, Wonnacott R, Heung M. Safety of arteriovenous fistulae and grafts for continuous renal replacement therapy: The Michigan experience. Hemodial Int 2018; 22:50.</a></li><li><a class="nounderline abstract_t">Dhondt A, Eloot S, Wachter DD, et al. Dialysate partitioning in the Genius batch hemodialysis system: effect of temperature and solute concentration. Kidney Int 2005; 67:2470.</a></li><li><a class="nounderline abstract_t">Dhondt AW, Vanholder RC, De Smet RV, et al. Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. Kidney Int 2003; 63:1540.</a></li><li><a class="nounderline abstract_t">Dhondt A, Verstraete A, Vandewoude K, et al. Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: the case of lithium intoxication therapy. Am J Kidney Dis 2005; 46:e95.</a></li><li><a class="nounderline abstract_t">Clark WR, Turk JE Jr. The NxStage System One. Semin Dial 2004; 17:167.</a></li><li><a class="nounderline abstract_t">Clark WR, Ronco C. Continuous renal replacement techniques. Contrib Nephrol 2004; 144:264.</a></li><li><a class="nounderline abstract_t">Tu A, Ahmad S. Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000; 29:620.</a></li><li><a class="nounderline abstract_t">Madison JR, Ilumin MP, Chin AI, et al. Citrate-containing dialysate is well tolerated during slow extended daily dialysis in the ICU. J Am Soc Nephrol 2005; 16:314A.</a></li><li><a class="nounderline abstract_t">Sigler MH, Teehan BP. Solute transport in continuous hemodialysis: a new treatment for acute renal failure. Kidney Int 1987; 32:562.</a></li><li><a class="nounderline abstract_t">Sigler MH. Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure. Adv Ren Replace Ther 1997; 4:68.</a></li><li><a class="nounderline abstract_t">Kudoh Y, Iimura O. Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 1. Theoretical consideration and new technique. Jpn Circ J 1988; 52:1171.</a></li><li><a class="nounderline abstract_t">Kudoh Y, Shiiki M, Sasa Y, et al. Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 2. Animal experiments and clinical implication. Jpn Circ J 1988; 52:1183.</a></li><li><a class="nounderline abstract_t">Wang N, Jiang L, Zhu B, et al. Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. Crit Care 2015; 19:371.</a></li><li><a class="nounderline abstract_t">Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60:777.</a></li><li><a class="nounderline abstract_t">Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36:294.</a></li><li><a class="nounderline abstract_t">Lonnemann G, Floege J, Kliem V, et al. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000; 15:1189.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Kretschmer U, Ernst T, et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43:342.</a></li><li><a class="nounderline abstract_t">Finkel KW, Foringer JR. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients. Ren Fail 2005; 27:541.</a></li><li><a class="nounderline abstract_t">Clark JA, Schulman G, Golper TA. Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008; 3:736.</a></li><li><a class="nounderline abstract_t">Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19:349.</a></li><li><a class="nounderline abstract_t">Wen M, Küchle C, Steubl D, et al. A novel citrate-based protocol versus heparin anticoagulation for sustained low-efficiency dialysis in the ICU: safety, efficacy, and cost. BMC Nephrol 2018; 19:79.</a></li><li><a class="nounderline abstract_t">Morgera S, Scholle C, Melzer C, et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98:c35.</a></li><li><a class="nounderline abstract_t">Schneider M, Liefeldt L, Slowinski T, et al. Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure. Int J Artif Organs 2008; 31:43.</a></li><li><a class="nounderline abstract_t">Morath C, Miftari N, Dikow R, et al. Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function. Nephrol Dial Transplant 2008; 23:421.</a></li><li><a class="nounderline abstract_t">Mushatt DM, Mihm LB, Dreisbach AW, Simon EE. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49:433.</a></li><li><a class="nounderline abstract_t">Dager WE. Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 2006; 34:240.</a></li><li><a class="nounderline abstract_t">Bogard KN, Peterson NT, Plumb TJ, et al. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011; 39:560.</a></li><li><a class="nounderline abstract_t">Roberts JA, Mehta RL, Lipman J. Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing? Crit Care Med 2011; 39:602.</a></li><li><a class="nounderline abstract_t">Jang SM, Lewis SJ, Mueller BA. Harmonizing antibiotic regimens with renal replacement therapy. Expert Rev Anti Infect Ther 2020; 18:887.</a></li><li><a class="nounderline abstract_t">Ahern J, Lai C, Rebuck J, et al. Experience with vancomycin in patients receiving slow low-efficiency dialysis. Hosp Pharm 2004; 39:138.</a></li><li><a class="nounderline abstract_t">Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437.</a></li><li><a class="nounderline abstract_t">Kielstein J, Czock D, Schopke T, et al. Pharmacokinetics and Elimination of Moxifloxacin in Intensive Care Unit Patients Undergoing Extended Daily Dialysis. J Am Soc Nephrol 2004; 15::.</a></li><li><a class="nounderline abstract_t">Kihara M, Ikeda Y, Fujita H, et al. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure. Blood Purif 1996; 14:20.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Czock D, Schöpke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51.</a></li><li><a class="nounderline abstract_t">Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24:267.</a></li><li><a class="nounderline abstract_t">Burkhardt O, Joukhadar C, Traunmüller F, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61:224.</a></li><li><a class="nounderline abstract_t">Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009; 34:282.</a></li><li><a class="nounderline abstract_t">Burkhardt O, Thon S, Burhenne J, et al. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010; 36:93.</a></li><li><a class="nounderline abstract_t">Cremaschi E, Maggiore U, Maccari C, et al. Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED). Minerva Anestesiol 2010; 76:961.</a></li><li><a class="nounderline abstract_t">Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1:1263.</a></li><li><a class="nounderline abstract_t">Deshpande P, Chen J, Gofran A, et al. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transplant 2010; 25:2632.</a></li><li><a class="nounderline abstract_t">Golestaneh L, Gofran A, Mokrzycki MH, Chen JL. Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Nephrol 2009; 72:286.</a></li><li><a class="nounderline abstract_t">Kihara M, Ikeda Y, Shibata K, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol 1994; 42:193.</a></li><li><a class="nounderline abstract_t">Kihara M, Ikeda Y, Shiratori K, et al. A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis. Nephron 1994; 68:406.</a></li><li><a class="nounderline abstract_t">Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66:291.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Lorenzen J, Kaever V, et al. Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case. Nephrol Dial Transplant 2009; 24:2283.</a></li><li><a class="nounderline abstract_t">Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27:808.</a></li><li><a class="nounderline abstract_t">Schmidt JJ, Strunk AK, David S, et al. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother 2019; 74:997.</a></li><li><a class="nounderline abstract_t">Dimski T, Brandenburger T, Janczyk M, et al. Elimination of fosfomycin during dialysis with the Genius system in septic patients. Sci Rep 2021; 11:12032.</a></li><li><a class="nounderline abstract_t">Gerecke LKV, Schmidt JJ, Hafer C, et al. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother 2021; 77:169.</a></li><li><a class="nounderline abstract_t">Schmidt JJ, Bode-Böger SM, Martens-Lobenhoffer J, et al. Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy. Clin J Am Soc Nephrol 2021; 16:1256.</a></li><li><a class="nounderline abstract_t">Eden G, Kühn-Velten WN, Hafer C, Kielstein JT. Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Stadler M, Czock D, et al. Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. Eur J Haematol 2005; 74:533.</a></li><li><a class="nounderline abstract_t">Eloot S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73:765.</a></li><li><a class="nounderline abstract_t">Zasuwa GA, Yee J, Passalacqua KD, Frinak S. Remote Monitoring of Sustained Low-Efficiency Dialysis (SLED) Machines in Intensive Care Unit. Kidney Med 2022; 4:100452.</a></li><li><a class="nounderline abstract_t">Fieghen HE, Friedrich JO, Burns KE, et al. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol 2010; 11:32.</a></li><li><a class="nounderline abstract_t">Kron J, Kron S, Wenkel R, et al. Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure. Nephrol Dial Transplant 2012; 27:146.</a></li><li><a class="nounderline abstract_t">Di Mario F, Regolisti G, Maggiore U, et al. Hypophosphatemia in critically ill patients undergoing Sustained Low-Efficiency Dialysis with standard dialysis solutions. Nephrol Dial Transplant 2022; 37:2505.</a></li><li><a class="nounderline abstract_t">Kihara M, Ikeda Y, Fujita H, et al. Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure. Intensive Care Med 1997; 23:110.</a></li><li><a class="nounderline abstract_t">Marshall M, Shaver M, Alam M, Chatoth D. Amino acid losses during sustained low efficiency dialysis (SLED). J Am Soc Nephrol 2000; 11:312A.</a></li><li><a class="nounderline abstract_t">Schmidt JJ, Hafer C, Spielmann J, et al. Removal characteristics and total dialysate content of glutamine and other amino acids in critically ill patients with acute kidney injury undergoing extended dialysis. Nephron Clin Pract 2014; 126:62.</a></li></ol></div><div id="topicVersionRevision">Topic 1903 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113696" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prolonged Intermittent Renal Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202815" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prolonged daily intermittent renal replacement therapy in ICU patients by ICU nurses and ICU physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16573441" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prolonged intermittent renal replacement therapy in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395893" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hybrid renal replacement modalities for the critically ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517979" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Low-efficiency acute renal replacement therapy: role in acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18218315" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sustained low-efficiency daily dialysis with hemofiltration for acute kidney injury in the presence of sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16850023" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15031344" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071958" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436091" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Accelerated venovenous hemofiltration: early technical and clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19218540" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17328843" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : [Hybrid or continuous renal replacement techniques for unstable haemodynamic patients in the intensive care unit].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202814" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877575" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Solute kinetics during extended daily hemodialysis in the intensive care unit (ICU)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407631" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818996" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Continuous versus intermittent renal replacement therapy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285591" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal replacement therapy in patients with acute renal failure: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32149415" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of renal replacement therapy modalities on renal recovery and mortality for acute kidney injury: A PRISMA-compliant systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21075821" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495376" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Declining mortality in patients with acute renal failure, 1988 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084171" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Has mortality from acute renal failure decreased? A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280066" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24349114" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extended daily dialysis in acute kidney injury patients: metabolic and fluid control and risk factors for death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26955212" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of dialysis practice patterns on outcomes in acute kidney injury in Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699474" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16326743" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Practice patterns in the management of acute renal failure in the critically ill patient: an international survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948196" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : International survey on the management of acute kidney injury in critically ill patients: year 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28289816" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27241853" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Continuous Dialysis Therapies: Core Curriculum 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093828" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Automated regional citrate anticoagulation: technological barriers and possible solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837726" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Improvement of cerebral blood flow patterns in hepatorenal syndrome using sustained low-efficiency dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889218" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Hybrid technologies of renal replacement therapy in the treatment of multiple organ failure in cardiosurgical patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634000" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Sustained low-efficiency dialysis (SLED) in patients with prevalent systolic heart failure refractory to medical treatment and with chronic renal failure].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644818" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : [Long-term sustained low efficiency dialysis in eight patients with class IV NYHA heart failure resistant to high-dose diuretic treatment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34941056" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sustained low efficiency dialysis is non-inferior to continuous renal replacement therapy in critically ill patients with acute kidney injury: A comparative meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457951" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dialysate and blood flow dependence of diffusive solute clearance during CVVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23171639" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : New high-cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: a clinical crossover comparison in extended dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34261420" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The landscape of renal replacement therapy in Veterans Affairs Medical Center intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917719" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Walkaway PIRRT (as SLED) for Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Patient safety in hemodialysis from the point of view of the DGfN equipment commission</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34191045" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Present practise patterns of renal replacement therapy in German intensive care medicine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295984" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety of arteriovenous fistulae and grafts for continuous renal replacement therapy: The Michigan experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882294" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dialysate partitioning in the Genius batch hemodialysis system: effect of temperature and solute concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631371" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253717" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: the case of lithium intoxication therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15043625" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The NxStage System One.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264415" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Continuous renal replacement techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Citrate-containing dialysate is well tolerated during slow extended daily dialysis in the ICU</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3430952" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Solute transport in continuous hemodialysis: a new treatment for acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996622" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3210294" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 1. Theoretical consideration and new technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3210295" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 2. Animal experiments and clinical implication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26494153" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11473662" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10922307" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910443" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14750100" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16152991" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18272829" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26415638" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29614970" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A novel citrate-based protocol versus heparin anticoagulation for sustained low-efficiency dialysis in the ICU: safety, efficacy, and cost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15361702" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18286453" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17913732" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580416" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Antibiotic dosing in slow extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374185" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21221000" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330868" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32362161" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Harmonizing antibiotic regimens with renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Experience with vancomycin in patients receiving slow low-efficiency dialysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599148" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacokinetics and Elimination of Moxifloxacin in Intensive Care Unit Patients Undergoing Extended Daily Dialysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8718561" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374156" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18723863" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965030" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369040" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Extended daily dialysis does not affect the pharmacokinetics of anidulafungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20381320" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102392" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699357" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181801" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19825334" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994939" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7838280" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013257" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pharmacokinetics of linezolid in septic patients with and without extended dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225017" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940903" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Higher renal replacement therapy dose delivery influences on drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30624668" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34103579" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Elimination of fosfomycin during dialysis with the Genius system in septic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34586373" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34301737" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29301798" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876260" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160958" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Impact of hemodialysis duration on the removal of uremic retention solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35518838" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Remote Monitoring of Sustained Low-Efficiency Dialysis (SLED) Machines in Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106112" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21622989" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35481705" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hypophosphatemia in critically ill patients undergoing Sustained Low-Efficiency Dialysis with standard dialysis solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037649" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Amino acid losses during sustained low efficiency dialysis (SLED)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577340" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Removal characteristics and total dialysate content of glutamine and other amino acids in critically ill patients with acute kidney injury undergoing extended dialysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
